482 related articles for article (PubMed ID: 23993766)
1. Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy.
Momattin H; Mohammed K; Zumla A; Memish ZA; Al-Tawfiq JA
Int J Infect Dis; 2013 Oct; 17(10):e792-8. PubMed ID: 23993766
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.
Yao TT; Qian JD; Zhu WY; Wang Y; Wang GQ
J Med Virol; 2020 Jun; 92(6):556-563. PubMed ID: 32104907
[TBL] [Abstract][Full Text] [Related]
3. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.
Vargas M; Servillo G; Einav S
Eur Rev Med Pharmacol Sci; 2020 Aug; 24(16):8592-8605. PubMed ID: 32894567
[TBL] [Abstract][Full Text] [Related]
4. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19.
Wu L; Zheng Y; Liu J; Luo R; Wu D; Xu P; Wu D; Li X
Aging (Albany NY); 2021 Apr; 13(8):10833-10852. PubMed ID: 33879634
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis.
Zhong H; Wang Y; Zhang ZL; Liu YX; Le KJ; Cui M; Yu YT; Gu ZC; Gao Y; Lin HW
Pharmacol Res; 2020 Jul; 157():104872. PubMed ID: 32360583
[TBL] [Abstract][Full Text] [Related]
7. Broad-spectrum coronavirus antiviral drug discovery.
Totura AL; Bavari S
Expert Opin Drug Discov; 2019 Apr; 14(4):397-412. PubMed ID: 30849247
[TBL] [Abstract][Full Text] [Related]
8. What are our pharmacotherapeutic options for MERS-CoV?
Al-Tawfiq JA; Memish ZA
Expert Rev Clin Pharmacol; 2014 May; 7(3):235-8. PubMed ID: 24580083
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial.
Arabi YM; Alothman A; Balkhy HH; Al-Dawood A; AlJohani S; Al Harbi S; Kojan S; Al Jeraisy M; Deeb AM; Assiri AM; Al-Hameed F; AlSaedi A; Mandourah Y; Almekhlafi GA; Sherbeeni NM; Elzein FE; Memon J; Taha Y; Almotairi A; Maghrabi KA; Qushmaq I; Al Bshabshe A; Kharaba A; Shalhoub S; Jose J; Fowler RA; Hayden FG; Hussein MA;
Trials; 2018 Jan; 19(1):81. PubMed ID: 29382391
[TBL] [Abstract][Full Text] [Related]
10. A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV).
Momattin H; Al-Ali AY; Al-Tawfiq JA
Travel Med Infect Dis; 2019; 30():9-18. PubMed ID: 31252170
[TBL] [Abstract][Full Text] [Related]
11. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
[TBL] [Abstract][Full Text] [Related]
12. [Potential antiviral therapeutics for 2019 Novel Coronavirus].
Li H; Wang YM; Xu JY; Cao B
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Mar; 43(3):170-172. PubMed ID: 32164080
[TBL] [Abstract][Full Text] [Related]
13. A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2.
Atzrodt CL; Maknojia I; McCarthy RDP; Oldfield TM; Po J; Ta KTL; Stepp HE; Clements TP
FEBS J; 2020 Sep; 287(17):3633-3650. PubMed ID: 32446285
[TBL] [Abstract][Full Text] [Related]
14. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
15. Current therapeutic options for coronavirus disease 2019 (COVID-19)-lessons learned from severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) therapy: a systematic review protocol.
Zhang ZL; Zhong H; Liu YX; Le KJ; Cui M; Yu YT; Gu ZC; Gao Y; Lin HW
Ann Transl Med; 2020 Nov; 8(22):1527. PubMed ID: 33313272
[TBL] [Abstract][Full Text] [Related]
16. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.
Bhatnagar T; Murhekar MV; Soneja M; Gupta N; Giri S; Wig N; Gangakhedkar R
Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):184-189. PubMed ID: 32362644
[TBL] [Abstract][Full Text] [Related]
17. Middle East Respiratory Syndrome Virus Pathogenesis.
Singh SK
Semin Respir Crit Care Med; 2016 Aug; 37(4):572-7. PubMed ID: 27486737
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the potential impact of targeted vaccination strategies against severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) outbreaks in the healthcare setting.
Abdirizak F; Lewis R; Chowell G
Theor Biol Med Model; 2019 Oct; 16(1):16. PubMed ID: 31587665
[TBL] [Abstract][Full Text] [Related]
19. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Martinez MA
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial.
Arabi YM; Asiri AY; Assiri AM; Aziz Jokhdar HA; Alothman A; Balkhy HH; AlJohani S; Al Harbi S; Kojan S; Al Jeraisy M; Deeb AM; Memish ZA; Ghazal S; Al Faraj S; Al-Hameed F; AlSaedi A; Mandourah Y; Al Mekhlafi GA; Sherbeeni NM; Elzein FE; Almotairi A; Al Bshabshe A; Kharaba A; Jose J; Al Harthy A; Al Sulaiman M; Mady A; Fowler RA; Hayden FG; Al-Dawood A; Abdelzaher M; Bajhmom W; Hussein MA;
Trials; 2020 Jan; 21(1):8. PubMed ID: 31900204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
